comparemela.com
Home
Live Updates
Catalyst Biosciences, Inc.: Catalyst Biosciences Completes First Steps in Reverse Merger Plan : comparemela.com
Catalyst Biosciences, Inc.: Catalyst Biosciences Completes First Steps in Reverse Merger Plan
Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5
Related Keywords
China ,
Ying Luo ,
Liaoning ,
Beijing ,
Japan ,
Tokyo ,
United States ,
Canada ,
Chinese ,
Trisha Colton ,
Nassim Usman ,
Augustine Lawlor ,
Raymond James ,
Thomas Eastling ,
Gibson ,
Catalyst Biosciences Inc ,
Nasdaq ,
Group Ltd ,
Group In Subsequent Transaction ,
Dunn Crutcher ,
Securities Exchange ,
Company Or Catalyst ,
Leadership Organization ,
Herrington Sutcliffe ,
Pharma Company ,
Acquire Controlling Interest ,
China Based Commercial Pharma Company ,
Special Dividend ,
Contingent Value Right ,
Meeting Planned ,
Host Conference Call Today ,
Beijing Continent ,
Mainland China ,
Catalyst Board ,
Andrea Hunt ,
Seline Miller ,
Chief Executive Officer ,
Interim Chief Financial Officer ,
Seriesx Preferred Stock ,
Preferred Stock ,
Business Combination ,
Business Combination Agreement ,
Catalyst Common Stock ,
Catalyst Biosciences ,
Securities Exchange Act ,
Securities Act ,
Minority Holders ,
Annual Report ,
Quarterly Reports ,
Current Reports ,
Additional Information Will ,
Catalyst ,
Iosciences ,
Ompletes ,
First ,
Steps ,
Reverse ,
Berger ,
Plan ,
comparemela.com © 2020. All Rights Reserved.